Ball AT et al (2024) Identification and development of cyclic peptide inhibitors of hypoxia inducible factors 1 and 2 that disrupt hypoxia-response signaling in cancer cells. J Am Chem Soc 146(13):8877–8886

CAS  PubMed  PubMed Central  Google Scholar 

Benak D et al (2025) Epitranscriptomic regulation of HIF-1: bidirectional regulatory pathways. Mol Med 31(1):105

CAS  PubMed  PubMed Central  Google Scholar 

Zhang J et al (2025) Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer. Cell Mol Biol Lett 30(1):2

CAS  PubMed  PubMed Central  Google Scholar 

Krishnan A, Ansari HK (2024) Molecular basis of response to hypoxia. Adaptation under stressful environments through biological adjustments and interventions. Springer, pp 21–40

Google Scholar 

Strocchi S et al (2022) The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation. Oncogene 41(29):3665–3679

Focaccio A et al (2024) A spotlight on the role of copper in the epithelial to mesenchymal transition. Life Sci 354:122972

Ubaid S et al (2024) Targeting HIF-1α in sickle cell disease and cancer: unraveling therapeutic opportunities and risks. Expert Opin Ther Targets 28(5):357–373

Machado-Oliveira G et al (2015) FBXL5 modulates HIF-1α transcriptional activity by degradation of CITED2. Arch Biochem Biophys 576:61–72

CAS  PubMed  Google Scholar 

Tipoe GL et al (2006) Expression and functions of vasoactive substances regulated by hypoxia-inducible factor-1 in chronic hypoxemia. Cardiovasc Hematol Agents Med Chem (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents) 4(3):199–218

Stampone E et al (2023) Genome editing and cancer therapy: handling the hypoxia-responsive pathway as a promising strategy. Cell Mol Life Sci 80(8):220

CAS  PubMed  PubMed Central  Google Scholar 

Ting KK (2024) Revisiting the role of hypoxia-inducible factors and nuclear factor erythroid 2-related factor 2 in regulating macrophage inflammation and metabolism. Front Cell Infect Microbiol 14:1403915

CAS  PubMed  PubMed Central  Google Scholar 

Ma J et al (2024) Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment. Proc Natl Acad Sci 121(10):e2309957121

CAS  PubMed  PubMed Central  Google Scholar 

Al-Ostoot FH, Salah S, Khanum SA (2024) An overview of cancer biology, pathophysiological development and it’s treatment modalities: current challenges of cancer anti-angiogenic therapy. Cancer Invest 42(7):559–604

CAS  PubMed  Google Scholar 

Rahman MA, Ali MM (2024) Recent treatment strategies and molecular pathways in resistance mechanisms of antiangiogenic therapies in glioblastoma. Cancers 16(17):2975

CAS  PubMed  PubMed Central  Google Scholar 

Chenchula S et al (2025) Combination therapies for the management of cancer immunotherapy. Nanotechnology based strategies for cancer immunotherapy: concepts, design, and clinical applications. Springer, pp 103–144

Google Scholar 

Li Z, You Q, Zhang X (2019) Small-molecule modulators of the hypoxia-inducible factor pathway: development and therapeutic applications. J Med Chem 62(12):5725–5749

CAS  PubMed  Google Scholar 

Hefny SM et al (2024) A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments. Eur J Med Chem 274:116527

CAS  PubMed  Google Scholar 

Zhang Y et al (2025) Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use. Signal Transduct Target Ther 10(1):44

PubMed  PubMed Central  Google Scholar 

Masci D et al (2024) Targeting CBP and p300: emerging anticancer agents. Molecules 29(19):4524

CAS  PubMed  PubMed Central  Google Scholar 

Constâncio V et al (2025) Prostate cancer epigenetics—from pathophysiology to clinical application. Nat Rev Urol 22:447–469

PubMed  Google Scholar 

Khot S et al (2024) Innovative drug delivery strategies for targeting glioblastoma: overcoming the challenges of the tumor microenvironment. Expert Opin Drug Deliv 21(12):1837–1857

CAS  PubMed  Google Scholar 

Famta P et al (2025) Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation. Drug Deliv Transl Res 15(2):389–406

PubMed  Google Scholar 

Wang W et al (2025) Lactate-induced protein lactylation in cancer: functions, biomarkers and immunotherapy strategies. Front Immunol 15:1513047

PubMed  PubMed Central  Google Scholar 

Danielpour D (2024) Advances and challenges in targeting tgf-β isoforms for therapeutic intervention of cancer: a mechanism-based perspective. Pharmaceuticals 17(4):533

CAS  PubMed  PubMed Central  Google Scholar 

McDermott A, Tavassoli A (2024) Hypoxia-inducible transcription factors: architects of tumorigenesis and targets for anticancer drug discovery. Transcription 16(1):86–117

PubMed  PubMed Central  Google Scholar 

Zong Z et al (2025) Emerging roles of lysine lactyltransferases and lactylation. Nat Cell Biol 27:563–574

CAS  PubMed  Google Scholar 

Cowman SJ, Koh MY (2022) Revisiting the HIF switch in the tumor and its immune microenvironment. Trends Cancer 8(1):28–42

CAS  PubMed  Google Scholar 

Ortmann BM (2024) Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. BMJ oncology 3(1):e000154

PubMed  PubMed Central  Google Scholar 

Jawad SF et al (2024) The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies. Cancer Metastasis Rev 43(1):5–27

CAS  PubMed  Google Scholar 

Xiao Y et al (2024) Targeted protein degradation: current and emerging approaches for E3 ligase deconvolution. J Med Chem 67(14):11580–11596

CAS  PubMed  Google Scholar 

Holdgate GA et al (2022) Drug discovery for epigenetics targets. Drug Discov Today 27(4):1088–1098

CAS  PubMed  Google Scholar 

Hyun K et al (2024) The BAF complex enhances transcription through interaction with H3K56ac in the histone globular domain. Nat Commun 15(1):9614

CAS  PubMed  PubMed Central  Google Scholar 

Porter RS et al (2025) Coordinated neuron-specific splicing events restrict nucleosome engagement of the LSD1 histone demethylase complex. Cell Rep 44(1):115213

CAS  PubMed  PubMed Central  Google Scholar 

Yang X et al (2025) Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment. Cell Death Discov 11:189

CAS  PubMed  PubMed Central  Google Scholar 

Chen Q (2022) Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents. Theranostics 12(11):4935–4948

CAS  PubMed  PubMed Central  Google Scholar 

Freedman SJ et al (2002) Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α. Proc Natl Acad Sci 99(8):5367–5372

CAS  PubMed  PubMed Central  Google Scholar 

Liang Z et al (2024) Molecular characterization and function of hif1a and fih1 in response to acute thermal stress in American shad (Alosa sapidissima). Fish Physiol Biochem 50:1563–1581

CAS  PubMed  Google Scholar 

Wang N et al (2024) P300/CBP regulates HIF-1–Dependent sympathetic activation and hypertension by intermittent hypoxia. Am J Respir Cell Mol Biol 70(2):110–118

CAS  PubMed  Google Scholar 

Xu L, Xuan H, Shi X (2025) Dysregulation of the p300/CBP histone acetyltransferases in human cancer. Epigenomics 17(3):193–208

CAS  PubMed  Google Scholar 

Minisini M et al (2024) Acetylation and phosphorylation in the regulation of hypoxia-inducible factor activities: additional options to modulate adaptations to changes in oxygen levels. Life 14(1):20

CAS  Google Scholar 

Perez-Perri JI, Acevedo JM, Wappner P (2011) Epigenetics: new questions on the response to hypoxia. Int J Mol Sci 12(7):4705–4721

CAS  PubMed  PubMed Central  Google Scholar